Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
John A. McCauley(United States Military Academy), Charles McIntyre, Michael T. Rudd, Kevin T. Nguyen, Joseph J. Romano, John W. Butcher, Kevin F. Gilbert, Kimberly J. Bush, M. Katharine Holloway, John Swestock, Bang-Lin Wan, Steven S. Carroll, Jillian DiMuzio, Donald J. Graham, Steven W. Ludmerer, Shi‐Shan Mao, Mark W. Stahlhut, Christine Fandozzi, Nicole Trainor, David B. Olsen, Joseph P. Vacca, Nigel J. Liverton
Cited by 177
Abstract
A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular-modeling derived strategy. Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of compounds via a modular synthetic strategy allowed for the optimization of enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 35b (vaniprevir, MK-7009), which is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes and has good plasma exposure and excellent liver exposure in multiple species.
Related Papers
Efficient and Recyclable Monomeric and Dendritic Ru-Based Metathesis Catalysts
Steven B. Garber, Jason S. Kingsbury, Brian L. Gray et al.|Journal of the American Chemical Society|2000|2k
Olefin Metathesis-Active Ruthenium Complexes Bearing a Nucleophilic Carbene Ligand
Jinkun Huang, Edwin D. Stevens, Steven P. Nolan et al.|Journal of the American Chemical Society|1999|997